JP2022505866A - 直交タンパク質ヘテロ二量体 - Google Patents

直交タンパク質ヘテロ二量体 Download PDF

Info

Publication number
JP2022505866A
JP2022505866A JP2021522940A JP2021522940A JP2022505866A JP 2022505866 A JP2022505866 A JP 2022505866A JP 2021522940 A JP2021522940 A JP 2021522940A JP 2021522940 A JP2021522940 A JP 2021522940A JP 2022505866 A JP2022505866 A JP 2022505866A
Authority
JP
Japan
Prior art keywords
polypeptide
target
domain
monomer
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021522940A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505866A5 (cg-RX-API-DMAC7.html
Inventor
チェン,ジボ
ボーイケン,スコット
ベルメオ,シェリー
ランガン,ロバート,エー.
ベイカー,デイビッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WASHINGTON, University of
Original Assignee
WASHINGTON, University of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WASHINGTON, University of filed Critical WASHINGTON, University of
Publication of JP2022505866A publication Critical patent/JP2022505866A/ja
Publication of JP2022505866A5 publication Critical patent/JP2022505866A5/ja
Priority to JP2024107533A priority Critical patent/JP2024149492A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/002—Biomolecular computers, i.e. using biomolecules, proteins, cells
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03K—PULSE TECHNIQUE
    • H03K19/00—Logic circuits, i.e. having at least two inputs acting on one output; Inverting circuits
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/10—Boolean models
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/30—Dynamic-time models
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/914—Protein engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Theoretical Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Medical Informatics (AREA)
  • Mathematical Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Computing Systems (AREA)
  • Evolutionary Biology (AREA)
  • Wood Science & Technology (AREA)
  • Artificial Intelligence (AREA)
JP2021522940A 2018-11-02 2019-11-04 直交タンパク質ヘテロ二量体 Pending JP2022505866A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024107533A JP2024149492A (ja) 2018-11-02 2024-07-03 直交タンパク質ヘテロ二量体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862755264P 2018-11-02 2018-11-02
US62/755,264 2018-11-02
US201962904800P 2019-09-24 2019-09-24
US62/904,800 2019-09-24
PCT/US2019/059654 WO2020093043A1 (en) 2018-11-02 2019-11-04 Orthogonal protein heterodimers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024107533A Division JP2024149492A (ja) 2018-11-02 2024-07-03 直交タンパク質ヘテロ二量体

Publications (2)

Publication Number Publication Date
JP2022505866A true JP2022505866A (ja) 2022-01-14
JP2022505866A5 JP2022505866A5 (cg-RX-API-DMAC7.html) 2022-11-11

Family

ID=68655751

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021522940A Pending JP2022505866A (ja) 2018-11-02 2019-11-04 直交タンパク質ヘテロ二量体
JP2024107533A Pending JP2024149492A (ja) 2018-11-02 2024-07-03 直交タンパク質ヘテロ二量体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024107533A Pending JP2024149492A (ja) 2018-11-02 2024-07-03 直交タンパク質ヘテロ二量体

Country Status (8)

Country Link
US (4) US11820800B2 (cg-RX-API-DMAC7.html)
EP (1) EP3873919A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022505866A (cg-RX-API-DMAC7.html)
KR (1) KR20210087959A (cg-RX-API-DMAC7.html)
CN (1) CN113272317A (cg-RX-API-DMAC7.html)
AU (1) AU2019371462A1 (cg-RX-API-DMAC7.html)
CA (1) CA3117841A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020093043A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210087959A (ko) * 2018-11-02 2021-07-13 유니버시티 오브 워싱톤 직교 단백질 이종이량체
US20230399660A1 (en) * 2020-10-23 2023-12-14 Altius Institute For Biomedical Sciences Cell Permeable Proteins for Genome Engineering
WO2022169913A2 (en) * 2021-02-02 2022-08-11 Outpace Bio, Inc. Synthetic degrader system for targeted protein degradation
WO2023288190A1 (en) * 2021-07-13 2023-01-19 University Of Washington Modular reconfigurable asymmetric protein assemblies
WO2023150649A2 (en) * 2022-02-02 2023-08-10 Outpace Bio, Inc. Synthetic degrader system for targeted protein degradation
US20250136652A1 (en) * 2022-03-02 2025-05-01 The Regents Of The University Of California Fusion protein for targeting recombinant proteins for degradation
WO2024026465A1 (en) * 2022-07-29 2024-02-01 The Broad Institute, Inc. Programmable pattern recognition compositions
WO2026055533A1 (en) * 2024-09-06 2026-03-12 The Regents Of The University Of California Synthetic receptors for engineered ligands

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11512620A (ja) * 1995-10-06 1999-11-02 ペンス 発現されたタンパク質の検出および精製のためのコイルドコイルヘテロダイマー法および組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ507886A (en) * 1998-05-19 2003-05-30 Avidex Ltd Multivalent T cell receptor complexes
WO2004007530A2 (en) * 2002-07-17 2004-01-22 The Center For Blood Research, Inc. Modified proteins stabilized in a desired conformation and methods for producing same
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
US9217011B2 (en) * 2007-09-07 2015-12-22 Complix Nv Non-natural proteinaceous scaffold made of three non-covalently associated peptides
US20110224404A1 (en) 2010-03-11 2011-09-15 Florida State University Research Foundation Method for development of a peptide building block useful for de novo protein design
EP3436470A4 (en) 2016-04-01 2019-11-20 University of Washington POLYPEPTIDES FOR THE PREPARATION OF HOMOOLIGOMERS WITH MODULAR HYDROGEN BONDING NETWORKED SPECIFICITY AND THEIR DESIGN
US20180068054A1 (en) * 2016-09-06 2018-03-08 University Of Washington Hyperstable Constrained Peptides and Their Design
US10818377B2 (en) * 2016-11-16 2020-10-27 University Of Washington Computational design of self-assembling cyclic protein homo-oligomers
US20210363214A1 (en) * 2018-03-01 2021-11-25 University Of Washington Transmembrane polypeptides
CN112512544B (zh) * 2018-07-19 2025-09-09 华盛顿大学 蛋白质开关的全新设计
US20210324011A1 (en) * 2018-10-25 2021-10-21 University Of Washington Self-assembling protein homo-polymers
KR20210087959A (ko) * 2018-11-02 2021-07-13 유니버시티 오브 워싱톤 직교 단백질 이종이량체
KR20210111761A (ko) * 2018-12-04 2021-09-13 유니버시티 오브 워싱턴 단백질 기능 및 상호작용을 제어하기 위한 시약 및 방법
US12583896B2 (en) * 2019-01-07 2026-03-24 The Regents Of The University Of California Caged-degron-based molecular feedback circuits and methods of using the same
EP3908592A1 (en) * 2019-01-07 2021-11-17 University of Washington De novo design of protein switches for tunable control of protein degradation
WO2020214549A1 (en) * 2019-04-15 2020-10-22 University Of Washington Self-assembling 2d arrays with de novo protein building blocks
US20220144895A1 (en) * 2019-04-18 2022-05-12 University Of Washington De novo design of tunable ph-driven conformational switches
WO2020257225A1 (en) * 2019-06-17 2020-12-24 University Of Washington De novo design of phosphorylation inducible protein switches (phospho-switches)
WO2021158849A1 (en) * 2020-02-07 2021-08-12 University Of Washington Multipartite and circularly permuted beta-barrel polypeptides and methods for their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11512620A (ja) * 1995-10-06 1999-11-02 ペンス 発現されたタンパク質の検出および精製のためのコイルドコイルヘテロダイマー法および組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. MOL. BIOL., vol. Vol.428, p.385-398, JPN6023053954, 2016, ISSN: 0005403361 *

Also Published As

Publication number Publication date
US20220017579A1 (en) 2022-01-20
AU2019371462A1 (en) 2021-05-20
JP2024149492A (ja) 2024-10-18
WO2020093043A1 (en) 2020-05-07
CN113272317A (zh) 2021-08-17
US20220098250A1 (en) 2022-03-31
EP3873919A1 (en) 2021-09-08
US20210355175A1 (en) 2021-11-18
CA3117841A1 (en) 2020-05-07
KR20210087959A (ko) 2021-07-13
US11820800B2 (en) 2023-11-21
US20240101615A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
US20240101615A1 (en) Orthogonal protein heterodimers
Tiede et al. Adhiron: a stable and versatile peptide display scaffold for molecular recognition applications
Binz et al. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins
Ebersbach et al. Affilin–novel binding molecules based on human γ-B-crystallin, an all β-sheet protein
Guellouz et al. Selection of specific protein binders for pre-defined targets from an optimized library of artificial helicoidal repeat proteins (alphaRep)
JP2004508033A (ja) 反復モジュールを含む反復タンパク質の集合体
Rupert et al. A new DNA-binding motif in the Skn-1 binding domain–DNA complex
EP2161278B1 (en) Single-chain coiled coil scaffold
Patel et al. Selection of a high-affinity WW domain against the extracellular region of VEGF receptor isoform-2 from a combinatorial library using CIS display
Yasunaga et al. Structurally similar but functionally diverse ZU5 domains in human erythrocyte ankyrin
JP5904565B2 (ja) 微小タンパク質の骨格構造に基づく分子ライブラリ
Mason et al. Role of hydrophobic and electrostatic interactions in coiled coil stability and specificity
Markússon et al. High-affinity anti-Arc nanobodies provide tools for structural and functional studies
Lorenz et al. The filamentous phages fd and IF1 use different mechanisms to infect Escherichia coli
Manukian et al. pH-dependent compaction of the intrinsically disordered poly-E motif in titin
Meyer et al. Insights into molecular interactions between the juxtamembrane and kinase subdomains of the Arabidopsis Crinkly-4 receptor-like kinase
Xie et al. Structural insights into the recognition of phosphorylated Hop1 by Mek1
Deng et al. A heterospecific leucine zipper tetramer
WO2023288190A1 (en) Modular reconfigurable asymmetric protein assemblies
Panigrahi et al. The design and structure of outer membrane receptors from peroxisomes, mitochondria, and chloroplasts
JP2009112282A (ja) 極微小タンパク質およびその結晶
Wezner-Ptasińska et al. Design and characteristics of a stable protein scaffold for specific binding based on variable lymphocyte receptor sequences
Liu et al. Synthesis, physicochemical characterization, and crystallization of a putative retro‐coiled coil
Markússon et al. High-affinity nanobodies as tools for structural and functional studies on mammalian Arc
Nikolaev et al. Rethinking Leucine Zipper–a ubiquitous signal transduction motif

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240401

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240828